Last reviewed · How we verify
EV71 Vaccine only
The EV71 vaccine stimulates the immune system to produce antibodies and cellular immunity against Enterovirus 71, preventing infection and disease.
The EV71 vaccine stimulates the immune system to produce antibodies and cellular immunity against Enterovirus 71, preventing infection and disease. Used for Prevention of Enterovirus 71 infection and hand, foot, and mouth disease (HFMD) in infants and young children.
At a glance
| Generic name | EV71 Vaccine only |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated viral vaccine |
| Target | Enterovirus 71 (EV71) viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is an inactivated viral vaccine containing killed Enterovirus 71 particles that triggers both humoral (antibody) and cell-mediated immune responses. Upon vaccination, the immune system recognizes viral antigens and develops protective immunity, reducing the risk of EV71 infection and associated hand, foot, and mouth disease (HFMD), particularly severe neurological complications in young children.
Approved indications
- Prevention of Enterovirus 71 infection and hand, foot, and mouth disease (HFMD) in infants and young children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Loss of appetite
Key clinical trials
- Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). (PHASE1, PHASE2)
- Clinical Trial for Batch Consistency of EV71 Vaccine (PHASE4)
- Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine (PHASE4)
- Immunogenicity and Safety of Enterovirus Type 71 Vaccine,Inactivated(Vero Cells) in Volunteers Aged From 6 to 71 Months (PHASE2)
- Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine (PHASE4)
- Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children
- Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines (PHASE4)
- Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EV71 Vaccine only CI brief — competitive landscape report
- EV71 Vaccine only updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI